{
    "id": 19247,
    "cites": 58,
    "cited_by": 6,
    "reference": [
        "Akscin, J. and T. R. Barr (2007). Key practice indicators in o ce-based oncology practices: 2007 report on 2006 data. Journal of Oncology Practice 3(4), 200\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c203.",
        "Andrews, D. W. (2003). Tests for parameter instability and structural change with unknown change point: A corrigendum. Econometrica 71(1), 395\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c397.",
        "Arriagada R. et al. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 351\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c360.",
        "Ballatori, E., F. Roila, B. Ruggeri, M. Betti, S. sarti, G. Soru, G. Cruciani, M. D. Maio, B. Andrea, and R. Deuson (2007). The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Supportive Care in Cancer 15(2), 179\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c185.",
        "Barlas, S. (2011). Hospital outpatient pharmacies win higher medicare payments for 2011. Pharmacy and Therapeutics 36(1), 11\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c21.",
        "Belani C. P. et al. (2012). Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (h3emc -jmen): Results from a randomised, double-blind, phase 3 study. The Lancet Oncology 13(3), 292\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c299.",
        "Berndt, E. and J. P. Newhouse (2012). Pricing and reimbursement in u.s. pharmaceutical markets. In P. M. Danzon and S. Nicholson (Eds.), The Oxford Handbook of the Economics of the Biopharmaceutical Industry, pp. 201\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c265. Oxford UP.",
        "Booth C. M. et al. (2010). Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study. Journal of Clinical Oncology 28(21), 3472\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c3478.",
        "Butcher, L. (2008, April). Insurers and oncologists forge a better cancer drug policy. Managed Care Magazine.",
        "Chandra, A., D. M. Cutler, and Z. Song (2012). Who ordered that? the economics of treatment choices in medical care. In P. P. Barros, T. G. McGuire, and M. V. Pauly (Eds.), Handbook of Health Economics. Amsterdam: North-Holland.",
        "Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Disease 40(5), 373\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c383.",
        "Christensen, S. (1992). Volume responses to exogenous changes in medicare\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s payment policies. Health Services Research 27(1), 65\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c79.",
        "Clemens, J. and J. Gottlieb (2012). Do physicians\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 \u00c3\u00af\u00c2\u00ac\u00c2\u0081nancial incentives a\u00c3\u00a2\u00e2\u0080\u00a0\u00c2\u00b5ect medical treatment and patient health? SIEPR Discussion Paper 11-017.",
        "Colla, C. H., N. E. Morden, J. S. Skinner, J. R. Hoverman, and E. Meara (2012). Impact of payment reform on chemotherapy at the end of life. Journal of Oncology Practice 8(3s), e6s\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009ce13s.",
        "Community Oncology Alliance (2006). Community oncology alliance gathers in washington to address crisis in access to cancer care. Medical News Today.",
        "Davido\u00c3\u00a2\u00e2\u0080\u00a0\u00c2\u00b5, A. J., M. Tang, B. Seal, and M. J. Edelman (2010). Chemotherapy and survival bene\u00c3\u00af\u00c2\u00ac\u00c2\u0081t in elderly patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 28, 2191\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2197.",
        "Douillard J. et al. (2005). Anita: Phase iii adjuvant vinorelbine (n) and cisplatin (p) versus observation (obs) in completely resected (stage i-iii) non-small-cell lung cancer (nsclc) patients (pts): Final results after 70-month median follow-up. Journal of Clinical Oncology 23(16S June 1 Supplement)(Abstr. 7013).",
        "Douillard J. et al. (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ib-iiia non-small-cell lung cancer (anita): a randomised controlled trial. Lancet Oncology 7(9), 719\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c727.",
        "Earle, C. C., A. B. Nattinger, and A. L. Potosky (2002). Identifying cancer relapse using seer-medicare data. Medical Care 40(8 Supplemental), IV: 75\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c81.",
        "Encaoua, D. and A. Jacquemin (1980). Degree of monopoly, indices of concentration and threat of entry. Internation Economic Review 21(1), 87\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c105.",
        "Escarce, J. (1993). Medicare patients\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 use of overpriced procedures before and after the omnibus budget reconciliation act of 1987. American Journal of Public Health 83(3), 346\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c355.",
        "Friedman J. Y. et al. (2007). The medicare modernization act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care? Cancer 110(10), 2304\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2312.",
        "Government Accountability O ce (2001). Medicare physician fee schedule: Practice payments to oncologists indicate need for overall re\u00c3\u00af\u00c2\u00ac\u00c2\u0081nements. GAO-02-53.",
        "Government Accountability O ce (2004). Medicare chemotherapy payments: new drug and administration fees are closer to providers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 costs. GAO-05-142R.",
        "Grant, D. (2009). Physician \u00c3\u00af\u00c2\u00ac\u00c2\u0081nancial incentives and cesarean delivery: New conclusions from the healthcare cost and utilization project. Journal of Health Economics 28(1), 244\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c250.",
        "Gruber, J., J. Kim, and D. Mayzlin (1999). Physician fees and procedure intensity: the case of cesarean delivery. Journal of Health Economics 18(4), 473\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c490.",
        "Hurley, J. and R. Labelle (1995). Relative fees and the utilization of physician\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s services in canada. Health Economics 4, 419\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c438.",
        "Hurley, J., R. Labelle, and T. Rice (1990). The relationship between physician fees and the utilization of medical services in ontario. Advances in Health Economics and Health Services Research 11, 49\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c78.",
        "Jacobson, M., C. C. Earle, and J. P. Newhouse (2010). How medicare\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health A\u00c3\u00a2\u00e2\u0080\u00a0\u00c2\u00b5airs 29, 1391\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1399.",
        "Jacobson, M., C. C. Earle, and J. P. Newhouse (2011). Geographic variation in physicians \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 response to a reimbursement change. New England Journal of Medicine 365, 2049\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2052.",
        "Kaiser Family Foundation (2010). Kaiser family foundation medicare chartbook.",
        "Le Chevalier, T. (2003). Results of the randomized international adjuvant lung cancer trial (ialt): cisplatin-based chemotherapy (ct) vs no ct in 1867 patients (pts) with resected non-small cell lung cancer (nsclc). Proceedings of the American Society of Clinical Oncology 22(Abstr 6).",
        "McGuire, T. G. (2000). Physician agency. In A. J. Culyer and J. P. Newhouse (Eds.), Handbook of Health Economics, pp. 462\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c217. North-Holland.",
        "McGuire, T. G. and M. V. Pauly (1991). Physician response to fee changes with multiple payers. Journal of Health Economics 10(4), 385\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c410.",
        "MedPAC (2006). Report to the congress: e\u00c3\u00a2\u00e2\u0080\u00a0\u00c2\u00b5ects of medicare payment changes on oncology services.",
        "Mullen, P. (2007, June). The arrival of average sales price. Biotechnology Healthcare, 48\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c53.",
        "Newey, W. and K. West (1987). A simple, positive semi-de\u00c3\u00af\u00c2\u00ac\u00c2\u0081nite, heteroscedastic and autocorrelation consistent covariance matrix. Econometrica 55, 703\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c708.",
        "Nguyen, N. X. and F. W. Derrick (1997). Physician behavioral response to a medicare price reduction. Health Services Research 3, 283\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c298.",
        "O ce of Inspector General (1997a, December). Department of health and human services. excessive medicare payment for prescription drugs, no. oei-03-97-00290.",
        "O ce of Inspector General (1997b, December). Department of health and human services. excessive medicare payment for prescription drugs, no. oei-03-97-00290.",
        "Ramsey, S. D., J. F. Scoggins, D. K. Blough, C. L. McDermott, and C. M. Reyes (2009). Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. Journal of Managed Care Pharmacy 15(8), 659\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 668.",
        "Rice, T. (1983). The impact of changing medicare reimbursement rates on physicianinduced demand. Medical Care 21, 803\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c815.",
        "Rice, T. (1984). Physician-induced demand for medical care: New evidence from the medicare program. Advances in Health Economics and Health Services Research 5, 129\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c160.",
        "Rice, T. and R. Labelle (1989). Do physicians induce demand for medical services? Journal of Health Politics Policy Law 14, 587\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c600.",
        "Shainian, V. B., Y. Kuo, and S. Gilbert (2010). Reimbursement policy and androgendeprivation therapy for prostate cancer. New England Journal of Medicine 363, 1822\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1832.",
        "Shea, A. M., L. H. Curtis, B. G. Hammill, L. D. DiMartino, A. P. Abernethy, and K. A. Schulman (2008). Association between the medicare modernization act of 2003 and patient wait times and travel distance for chemotherapy. JAMA 300(2), 189\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c196.",
        "Skinner, J. (2012). Causes and consequences of regional variations in health care. In P. P. Barros, T. G. McGuire, and M. V. Pauly (Eds.), Handbook of Health Economics, Volume 2. Amsterdam: North-Holland.",
        "Stock, J. H. and M. W. Watson (2003). Introduction to Econometrics. Pearson Education, Inc.",
        "Struass G. et al. (2004, July). Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage ib non-small cell lung cancer (nsclc): Report of cancer and leukemia group b (calgb) protocol 9633. Journal of Clinical Oncology 22(14S).",
        "Struass G. et al. (2006, June). Adjuvant chemotherapy in stage ib non-small cell lung cancer (nsclc): Update of cancer and leukemia group b (calgb) protocol 9633. Journal of Clinical Oncology 24(18S).",
        "Struass G. et al. (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage ib non-small-cell lung cancer: Calgb 9633. Journal of Clinical Oncology 26(31), 5043\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c5051.",
        "Vera-Llonch, M., D. Weycker, and A. Glass (2011). Healthcare cost in patients with metastatic lung cancer receiving chemotherapy. BMC Health Services Research 11, 305.",
        "Warren, J. L., E. Feuer, A. L. Potosky, G. F. riley, and C. F. Lynch (1999). Use of medicare hospital and physician data to assess breast cancer incidence. Medical Care 37(5), 445\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c456.",
        "Warren, J. L., L. C. Harlan, A. Fahey, B. A. Virnig, J. L. Freeman, C. N. Klabunde, G. S. Cooper, and K. B. Knoft (2002). Utility of the seer-medicare data to identify chemotherapy use. Medical Care 40 Supplemental, IV:55\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c61.",
        "Weight, C. J., E. J. Klein, and J. S. Jones (2007). Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the u.s. medicare population.",
        "Winton T. et al. (2004, July). A prospective randomised trial of adjuvant vinorelbine (vin) and cisplatin (cis) in completely resected stage 1b and ii non small cell lung cancer (nsclc) intergroup jbr.10. Journal of Clinical Oncology 22(14S).",
        "Winton T. et al. (2005). Vinorelbine plus cisplatin vs. observation in resected nonsmall -cell lung cancer. New England Journal of Medicine 352(25), 2589\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2597.",
        "Yip, W. C. (1998). Physician response to medicare fee reductions: Changes in the volume of coronary artery bypass graft (cabg) surgeries in the medicare and private sectors. Journal of Health Economics 17, 675\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c699. -.050.05.1-.050.05.1 -12-9 -6-3 0 3 6 9 12 -12-9 -6-3 0 3 6 9 12-12-9 -6-3 0 3 6 9 12"
    ]
}